Salt-Sensitivity Blood Pressure Study in Healthy Subjects

Overseen By Jonathan S Williams, MD, MMSc

Age: 18 - 65

Sex: Any

Trial Phase: Academic

Sponsor: Brigham and Women's Hospital

Must not be taking: NSAIDs, Steroids, Decongestants, others

Disqualifiers: Pregnancy, Breastfeeding, Alcohol, Tobacco, others

Compensation: Varies

Number of Visits: Unknown

88 Participants Needed

Trial Summary

What is the purpose of this trial?

The purpose of this study is to investigate the role dietary salt plays in epigenetic regulation of blood pressure, focusing on the salt-sensitive regulatory enzyme Lysine-specific demethylase 1.

Eligibility Criteria

This trial is for healthy Caucasian or African American individuals aged 25-45, with normal blood pressure and no history of major diseases like hypertension, diabetes, or heart disease. Participants must not be overweight (BMI <25), drink more than 6oz alcohol weekly, use tobacco/drugs/NSAIDs, be pregnant/breastfeeding, have certain drug sensitivities or recent steroid use.

Inclusion Criteria

Age 25-45 years

Caucasian or African American

No gender preference (anticipate 50% female)

Exclusion Criteria

You drink more than 6 ounces of alcohol per week.

You have used illegal drugs.

You have been regularly using NSAIDs (like ibuprofen or naproxen) for a long time.

Treatment Details

Interventions

• Lysine-specific demethylase 1 inhibitor

Trial Overview The study aims to understand how dietary salt affects blood pressure regulation through the enzyme Lysine-specific demethylase 1. It will measure changes in vascular stiffness, kidney blood flow response to salt intake and aldosterone levels after Angiotensin II infusion.

Participant Groups

Group I: Afr-Amer risk allele Active Control 3 Interventions

African Americans carrying the LSD1 affected allele

Group II: Cauc risk allele Placebo Group 3 Interventions

Caucasians carrying the LSD1 affected allele

Group III: Cauc non-risk allele Placebo Group 3 Interventions

Caucasians carrying the LSD1 non-risk allele

Group IV: Afr-Amer non-risk allele Placebo Group 3 Interventions

African Americans carrying the LSD1 non-risk allele

Who Is Running the Clinical Trial?

Brigham and Women's Hospital

Lead Sponsor

Trials

1,694

Recruited

14,790,000+